Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons

Jose Mitjavila, Danielle Yin, Pushkar M. Kulkarni, Chiara Zanato, Ganesh A. Thakur, Ruth Ross, Iain Greig, Ken Mackie, Alex Straiker

Research output: Contribution to journalArticle

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

The cannabinoid signaling system is found throughout the CNS and its involvement in several pathological processes makes it an attractive therapeutic target. Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators – both negative (NAMs) and positive (PAMs) – of these receptors. NAMs of CB1 appeared first on the scene, followed more recently by PAMs. Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids. We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons. These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.

In this study we find that while two related compounds, GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacology. Notably we were able to separate the PAM- and agonist-like responses of GAT211 by examining the enantiomers of this racemic compound: GAT228 and GAT229. We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.

Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system. Because these compounds may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.
Original languageEnglish
Pages (from-to)475-481
Number of pages7
JournalPharmacological Research
Volume129
Early online date20 Nov 2017
DOIs
Publication statusPublished - Mar 2018

Fingerprint

Cannabinoids
Cannabinoid Receptor CB1
Neurons
Ligands
Neuronal Plasticity
Pathologic Processes
Pharmacology
2-arachidonylglycerol
Therapeutics

Keywords

  • Allosteric
  • Orthosteric
  • G protein-coupled receptor
  • Cannabinoid receptor
  • CB1

Cite this

Mitjavila, J., Yin, D., Kulkarni, P. M., Zanato, C., Thakur, G. A., Ross, R., ... Straiker, A. (2018). Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacological Research, 129, 475-481. https://doi.org/10.1016/j.phrs.2017.11.019

Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. / Mitjavila, Jose; Yin, Danielle; Kulkarni, Pushkar M.; Zanato, Chiara; Thakur, Ganesh A.; Ross, Ruth; Greig, Iain; Mackie, Ken; Straiker, Alex.

In: Pharmacological Research, Vol. 129, 03.2018, p. 475-481.

Research output: Contribution to journalArticle

Mitjavila, J, Yin, D, Kulkarni, PM, Zanato, C, Thakur, GA, Ross, R, Greig, I, Mackie, K & Straiker, A 2018, 'Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons' Pharmacological Research, vol. 129, pp. 475-481. https://doi.org/10.1016/j.phrs.2017.11.019
Mitjavila, Jose ; Yin, Danielle ; Kulkarni, Pushkar M. ; Zanato, Chiara ; Thakur, Ganesh A. ; Ross, Ruth ; Greig, Iain ; Mackie, Ken ; Straiker, Alex. / Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. In: Pharmacological Research. 2018 ; Vol. 129. pp. 475-481.
@article{1f1879ad3b894c9f94519e2368460dfe,
title = "Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons",
abstract = "The cannabinoid signaling system is found throughout the CNS and its involvement in several pathological processes makes it an attractive therapeutic target. Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators – both negative (NAMs) and positive (PAMs) – of these receptors. NAMs of CB1 appeared first on the scene, followed more recently by PAMs. Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids. We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons. These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.In this study we find that while two related compounds, GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacology. Notably we were able to separate the PAM- and agonist-like responses of GAT211 by examining the enantiomers of this racemic compound: GAT228 and GAT229. We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system. Because these compounds may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.",
keywords = "Allosteric, Orthosteric, G protein-coupled receptor, Cannabinoid receptor, CB1",
author = "Jose Mitjavila and Danielle Yin and Kulkarni, {Pushkar M.} and Chiara Zanato and Thakur, {Ganesh A.} and Ruth Ross and Iain Greig and Ken Mackie and Alex Straiker",
note = "Research was supported by NIH grants DA-009789 (RR), DA-026449 (RR), DA-003672 (RR), CIHR Proof of Principal Phase 1 grant 288645 (RR), EY24625 (AS), EY24717 (GT & AS), DA011322 (KM) and DA021696 (KM).",
year = "2018",
month = "3",
doi = "10.1016/j.phrs.2017.11.019",
language = "English",
volume = "129",
pages = "475--481",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons

AU - Mitjavila, Jose

AU - Yin, Danielle

AU - Kulkarni, Pushkar M.

AU - Zanato, Chiara

AU - Thakur, Ganesh A.

AU - Ross, Ruth

AU - Greig, Iain

AU - Mackie, Ken

AU - Straiker, Alex

N1 - Research was supported by NIH grants DA-009789 (RR), DA-026449 (RR), DA-003672 (RR), CIHR Proof of Principal Phase 1 grant 288645 (RR), EY24625 (AS), EY24717 (GT & AS), DA011322 (KM) and DA021696 (KM).

PY - 2018/3

Y1 - 2018/3

N2 - The cannabinoid signaling system is found throughout the CNS and its involvement in several pathological processes makes it an attractive therapeutic target. Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators – both negative (NAMs) and positive (PAMs) – of these receptors. NAMs of CB1 appeared first on the scene, followed more recently by PAMs. Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids. We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons. These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.In this study we find that while two related compounds, GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacology. Notably we were able to separate the PAM- and agonist-like responses of GAT211 by examining the enantiomers of this racemic compound: GAT228 and GAT229. We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system. Because these compounds may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.

AB - The cannabinoid signaling system is found throughout the CNS and its involvement in several pathological processes makes it an attractive therapeutic target. Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators – both negative (NAMs) and positive (PAMs) – of these receptors. NAMs of CB1 appeared first on the scene, followed more recently by PAMs. Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids. We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons. These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.In this study we find that while two related compounds, GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacology. Notably we were able to separate the PAM- and agonist-like responses of GAT211 by examining the enantiomers of this racemic compound: GAT228 and GAT229. We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system. Because these compounds may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.

KW - Allosteric

KW - Orthosteric

KW - G protein-coupled receptor

KW - Cannabinoid receptor

KW - CB1

U2 - 10.1016/j.phrs.2017.11.019

DO - 10.1016/j.phrs.2017.11.019

M3 - Article

VL - 129

SP - 475

EP - 481

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -